MedTrace Logo

A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers

NCT07539415 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-04-20

No results posted yet for this study

Summary

Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults

Conditions

Interventions

DRUG

DWRX5003

Microneedle patch containing Semaglutide

DRUG

DWC202502

Semagluide

DRUG

DWC202503

Semaglutide

OTHER

DWRX5003P

placebo microneedle patch

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-30
Primary Completion
2026-04-30
Completion
2026-08-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07539415 on ClinicalTrials.gov